Multiple sclerosis Cell Models for Research

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) affecting approximately 2.8 million people worldwide (WHO, 2023). It is the most common non-traumatic cause of neurological disability in young adults, with a median age of onset around 30 years. The disease is more common in women (female-to-male ratio ~3:1) and in regions farther from the equator. The exact cause remains unknown, but a combination of genetic susceptibility (e.g., HLA-DRB1*15:01) and environmental factors (e.g., vitamin D deficiency, Epstein-Barr virus infection) is implicated. MS is not directly fatal, but life expectancy is reduced by about 7 years. The clinical course varies: relapsing-remitting MS (RRMS) is the most common (85% of cases), while secondary progressive MS (SPMS) and primary progressive MS (PPMS) are more severe. The economic burden is substantial, with annual costs exceeding $28 billion in the US alone (NCI, 2021).

MS is a complex autoimmune disease involving interactions between immune cells (T cells, B cells, macrophages) and CNS-resident cells (microglia, astrocytes, oligodendrocytes). This complexity makes it an ideal model for studying immune-mediated tissue damage, blood-brain barrier (BBB) dysfunction, and myelin repair mechanisms. Key research questions include: What triggers the initial autoimmune response? How do genetic risk variants contribute to disease susceptibility? What are the mechanisms of neurodegeneration and remyelination failure? Gene-edited cell models, such as CRISPR knockout or knock-in lines of immune cells or glial cells, allow researchers to dissect the roles of specific genes in disease pathways, test potential therapeutics, and develop personalized treatment strategies.

The pathogenesis of MS involves several interconnected pathways:

1. T-cell activation and differentiation: Autoreactive CD4+ T cells (Th1 and Th17) are activated in the periphery and cross the BBB into the CNS.

2. BBB breakdown: Activated T cells and pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) disrupt tight junctions of endothelial cells, increasing BBB permeability.

3. Microglial activation and neuroinflammation: Activated microglia release pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and reactive oxygen species (ROS), contributing to oligodendrocyte damage.

4. Oligodendrocyte injury and demyelination: Oligodendrocytes are damaged by immune attack, leading to myelin loss and axonal degeneration.

5. Remyelination failure: In chronic lesions, oligodendrocyte precursor cells (OPCs) fail to differentiate into mature oligodendrocytes, leading to sustained demyelination.

Unlike cancer, MS is not characterized by somatic mutations but by germline genetic variants that increase susceptibility. Genome-wide association studies (GWAS) have identified over 200 risk loci, with the strongest association in the HLA region. The table below lists key risk genes and their effects (data from NCBI Gene and ClinVar):

Key signaling networks in MS include:

• • T cell receptor (TCR) signaling: Activation of TCR leads to NF-κB and AP-1 pathways, promoting pro-inflammatory cytokine production.
• • JAK-STAT pathway: Cytokines such as IL-6, IL-12, and IL-23 activate JAK-STAT signaling, driving Th17 differentiation.
• • NF-κB pathway: Central to inflammatory responses; activated by TNF-α, IL-1β, and TLR ligands.
• • MAPK pathway: ERK and p38 MAPK are involved in microglial activation and cytokine release.
• • PI3K/AKT pathway: Regulates cell survival and proliferation of immune cells.

Gene editing of these pathway components in relevant cell lines (e.g., T cells, microglia) can help identify therapeutic targets.

Common cell lines used in MS research include:

Organoids, such as brain organoids derived from induced pluripotent stem cells (iPSCs), offer a more physiologically relevant 3D model that recapitulates cell-cell interactions and can be used to study neuroinflammation and myelination.

Animal models are essential for studying MS pathogenesis and testing therapies. Common models include:

• • Experimental autoimmune encephalomyelitis (EAE): The most widely used model; induced by immunization with myelin antigens or adoptive transfer of encephalitogenic T cells.
• • Cuprizone-induced demyelination: A toxin-based model that causes oligodendrocyte death and demyelination, useful for studying remyelination.
• • Viral-induced models: Theiler's murine encephalomyelitis virus (TMEV) infection leads to chronic demyelination.
• • Transgenic models: Mice expressing human HLA-DR2 (e.g., DR2b) and human T cell receptors are used to study genetic susceptibility.

These models have limitations, but they provide valuable insights into disease mechanisms.

CRISPR-based gene editing has revolutionized MS research by enabling the creation of isogenic cell lines with specific genetic modifications. These models allow researchers to study the functional impact of disease-associated variants in a controlled background. Examples include:

• • HLA-DRB1 knockout in antigen-presenting cells: To study the role of HLA-DR2 in antigen presentation and T cell activation.
• • IL7R knock-in with the risk variant rs6897932: To examine how this variant affects IL-7 signaling and T cell survival.
• • TNFRSF1A knockout in microglia: To investigate the role of TNF signaling in neuroinflammation.
• • CYP27B1 knockout in T cells: To study the effect of vitamin D metabolism on immune responses.

These gene-edited cell lines are commercially available from various sources, ensuring sequence verification and quality control. They are essential for target validation, drug screening, and functional genomics studies.

Gene-edited cell lines are powerful tools for functional genomics. By knocking out or knocking in specific genes, researchers can determine their role in disease pathways. For example:

• • Knockout of IL2RA in T cells: Reduces CD25 expression, impairing regulatory T cell function and increasing autoreactivity.
• • Knock-in of IL7R risk variant: Enhances IL-7 signaling, promoting survival of autoreactive T cells.
• • Knockout of CLEC16A in B cells: Affects autophagy and antigen presentation, altering B cell responses.

These models help validate GWAS hits and identify novel therapeutic targets.

Isogenic cell line pairs (e.g., wild-type vs. knockout) are ideal for drug screening. They allow researchers to assess the on-target effects of compounds and identify resistance mechanisms. For example:

• • Screening for anti-inflammatory drugs: Using microglial cell lines with or without TNFRSF1A knockout to test compounds that modulate TNF signaling.
• • Testing immunomodulatory drugs: Using T cell lines with or without IL7R risk variant to evaluate drugs that target IL-7 signaling.
• • Resistance studies: Chronic exposure to drugs can select for resistant cells; gene editing can help identify mutations that confer resistance.

CRISPR-based screens, such as synthetic lethality screens, can identify genes that are essential for cell survival in the presence of specific genetic backgrounds. This approach can uncover biomarkers for disease progression and treatment response. For example:

• • Synthetic lethality screen in microglia: Identify genes that, when knocked out, sensitize cells to inflammatory stimuli, potentially revealing new drug targets.
• • CRISPR activation screens: Overexpress genes to identify those that promote remyelination in oligodendrocyte precursor cells.

These screens can lead to the discovery of novel biomarkers and therapeutic strategies.